Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, Lugano, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland.
Asian Cardiovasc Thorac Ann. 2023 Nov;31(9):795-801. doi: 10.1177/02184923231209858. Epub 2023 Oct 24.
The quality of a myocardial protection of a single-dose del Nido cardioplegia versus multiple dose blood-based cardioplegia on myocardial injury, outcomes and operative times in patients undergoing minimally invasive aortic valve replacement is basically unreported.
Preoperative and post-operative data, as well as technical details from isolated minimally invasive aortic valve replacements, performed using single-dose or multiple-dose cardioplegia were prospectively collected and retrospectively analysed. A total of 110 patients undergoing minimally invasive valve replacements at our institution composed two groups: 55 patients in the blood cardioplegia group (BloCa) and 55 in the del Nido group (DeNiCa). The two-matched groups were comparable in terms of preoperative variables. In the DeNiCa group, there was a statistically significant less need for cardiac defibrillation after aortic cross-clamp release ( < 0.001). Moreover, the BloCa group received intraoperatively more blood transfusions ( = 0.001) and more insulin administration for higher glucose levels ( < 0.001). The BloCa group showed higher intraoperative lactate levels ( = 0.01). Need for post-operative inotropic and vasoactive support, Creatine Kinase-MB levels after 6 and 12 h, onset of post-operative atrial fibrillation and length of stay were similar. No deaths occurred in neither groups.
Single-dose del Nido cardioplegia in the setting of minimally invasive aortic surgery seems to offer adequate myocardial protection, comparable to multiple dose hematic cardioplegia. It has been documented a lower peri-operative need of defibrillation after cross-clamp release, lactate- and glucose peak values, as well as less blood transfusions compared to blood cardioplegic strategy.
在微创主动脉瓣置换术中,单次剂量 Del Nido 停搏液与多次剂量含血停搏液对心肌损伤、结果和手术时间的心肌保护质量基本没有报道。
前瞻性收集并回顾性分析了使用单次剂量或多次剂量停搏液进行微创主动脉瓣置换术的患者的术前和术后数据以及技术细节。我院共进行了 110 例微创瓣膜置换术,其中 55 例患者接受含血停搏液(BloCa)治疗,55 例患者接受 Del Nido 停搏液(DeNiCa)治疗。两组患者在术前变量方面具有可比性。在 DeNiCa 组,主动脉阻断夹释放后需要心脏除颤的情况明显减少( < 0.001)。此外,BloCa 组术中需要输注更多的血液( = 0.001),并且需要更多的胰岛素来控制更高的血糖水平( < 0.001)。BloCa 组术中的乳酸水平更高( = 0.01)。术后需要使用正性肌力药和血管活性药物支持、术后 6 小时和 12 小时的肌酸激酶-MB 水平、术后心房颤动的发生和住院时间相似。两组均无死亡病例。
微创主动脉手术中单次剂量的 Del Nido 停搏液似乎提供了足够的心肌保护,与多次剂量含血停搏液相当。与含血停搏液策略相比,单次剂量 Del Nido 停搏液可减少术后除颤的需求、乳酸和葡萄糖峰值以及血液输注量。